Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Cyramza ® (ramucirumab)
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
VEGFR-2 is the key mediator of VEGF-induced angiogenesis. Ramucirumab is a human receptor-targeted antibody that specifically binds VEGFR-2 and blocks binding of
VEGF-A
VEGF-C, and
VEGF-D.1
As a result, ramucirumab inhibits ligand–stimulated activation of VEGFR-2 and its downstream signaling components, including p44/p42 mitogen-activated protein kinases, neutralizing ligand-induced proliferation and migration of human endothelial cells.1
The mechanism of action for ramucirumab is illustrated in Figure 1.
Figure 1. Mechanism of Action1
Abbreviations: VEGF = vascular endothelial growth factor; VEGF-A = vascular endothelial growth factor-A; VEGF-C vascular endothelial growth factor-C; VEGF-D = vascular endothelial growth factor-D.
1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Glossary
VEGF = vascular endothelial growth factor
VEGF-A = vascular endothelial growth factor-A
VEGF-C = vascular endothelial growth factor-C
VEGF-D = vascular endothelial growth factor-D
VEGFR-2 = vascular endothelial growth factor receptor 2
Datum fӧr senaste ӧversyn 2018 M12 03